dm+d
Unassigned
New Medicines
Attention-deficit hyperactivity disorder (ADHD) in adults
Information
New molecular entity
Otsuka
Neurovance
Development and Regulatory status
None
None
Phase III Clinical Trials
Category
Triple neurotransmitter uptake inhibitor (noradrenaline, dopamine, serotonin)
Estimated prevalence of childhood ADHD in the UK is about 2.4% overall [3], with a significant male bias (3.62% vs. 0.85%) [4]. Only about 15% retain the full diagnosis in adulthood, however a further 50% still have some symptoms (partial remission) with continuing functional impairment including psychological, social, or educational difficulties [3].
Attention-deficit hyperactivity disorder (ADHD) in adults
Oral